Transaction DateRecipientSharesTypePriceValue
8th September 2020Bros. Advisors Lp Baker6,151Open or private purchase$47.39$291,479.90
8th September 2020Bros. Advisors Lp Baker15,807Open or private purchase$47.04$743,482.25
8th September 2020Bros. Advisors Lp Baker15,172Open or private purchase$47.47$720,199.67
8th September 2020Bros. Advisors Lp Baker76,473Open or private purchase$47.39$3,623,856.64
8th September 2020Bros. Advisors Lp Baker185Open or private purchase$45.88$8,486.88
8th September 2020Bros. Advisors Lp Baker1,220Open or private purchase$47.47$57,912.18
8th September 2020Bros. Advisors Lp Baker1,272Open or private purchase$47.04$59,828.52
8th September 2020Bros. Advisors Lp Baker15Open or private purchase$45.88$688.13
4th September 2020Bros. Advisors Lp Baker26,238Open or private purchase$47.26$1,239,984.27
4th September 2020Bros. Advisors Lp Baker712Open or private purchase$47.50$33,818.72
Kodiak Sciences
Kodiak Sciences logo

Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company. The company engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; K SI-501 for DME and uveitis.

Ticker: KOD
Sector: Health Technology
Industry: Biotechnology
SEC Central Index Key (CIK): 1468748
Employees: 39
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Fundamentals
Cash at Carrying Value: $270 M (0%)
Marketable Securities, Current: $147 M (18%)
Assets, Current: $419 M (23%)
Property, Plant and Equipment, Net: $1 M (11%)
Other Assets, Noncurrent: $8 M (49%)
Assets: $429 M (19%)
Accounts Payable, Current: $7 M (168%)
Accrued Liabilities, Current: $11 M (0%)
Liabilities, Current: $19 M (60%)
Other Liabilities, Noncurrent: $276 Th (-6%)
Liabilities: $120 M (789%)
Common Stock, Value, Issued: $5 Th (0%)
Common Stock, Shares, Issued: $45 M (0%)
Additional Paid in Capital, Common Stock: $517 M (2%)
Retained Earnings (Accumulated Deficit): $209 M (31%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $594 Th (5840%)
Stockholders' Equity (Parent): $309 M (0%)
Liabilities and Equity: $429 M (19%)
Research and Development: $21 M (-49%)
General and Administrative Expenses: $6 M (-47%)
Operating Income/Loss: $27 M (-48%)